This post was originally published on this site Cancer scars our insides and outsides, but it’s hard to know which it affects more. Cancer affects the body, but the impact of treatment — from chemotherapy to radiotherapy to immunotherapy to stem cell transplants — is highly psychological. My body is slowly healing, but the hardest…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted priority review to the application seeking trastuzumab deruxtecan‘s (DS-8201) approval for the treatment of metastatic HER2-positive breast cancer. The agency has set a Prescription Drug User Fee Act action date for the second quarter of 2020. By then,…
This post was originally published on this site The U.K.’s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology‘s Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube and peritoneal cancer who responded to platinum-based chemotherapy, regardless of their BRCA status or previous…
This post was originally published on this site Taking Xpovio (selinexor) in combination with the steroid dexamethasone leads to promising responses in heavily treated patients with relapsed or refractory multiple myeloma, a Phase 2 trial shows. The trial’s findings were reported in “Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma,” a study published in the New…
This post was originally published on this site People with non-Hodgkin’s lymphoma who are HIV-positive and have not received antiretroviral therapy — a treatment that stops HIV from replicating — have similar outcomes on standard R-CHOP chemotherapy, compared to those who have already started their HIV treatment, a retrospective study found. The study suggests that HIV-positive…
This post was originally published on this site A Phase 1/2 clinical trial assessing the cancer vaccine galinpepimut-S in combination with Keytruda (pembrolizumab) as a treatment for WT-1-positive advanced cancers has started dosing patients, Sellas Life Sciences announced. Galinpepimut-S is a cancer vaccine developed by Sellas to target the Wilms tumor 1 (WT1) protein. WT1…
This post was originally published on this site Adding the immunotherapy Keytruda (pembrolizumab) to chemotherapy increases the number of women with early triple-negative breast cancer who clear all signs of cancer, and tends to prolong survival without complications or symptoms, according to the latest results from the KEYNOTE-522 trial. “The data suggest that the improved pathological…
This post was originally published on this site Adding Erleada (apalutamide) to standard androgen deprivation therapy (ADT) increases the survival and delays disease progression in men with metastatic castration-sensitive prostate cancer (mCSPC) — and does so without compromising their quality of life — a Phase 3 clinical trial shows. Those findings were presented in the…
This post was originally published on this site To allow patients to focus on treatment and not cost, the HealthWell Foundation is offering copayment and insurance premium assistance to people with mantle cell lymphoma (MCL) who are on Medicare. The non-profit organization will provide up to $8,500 in financial aid as a yearlong grant to…
This post was originally published on this site Men who see their prostate cancer returning after surgery see no benefits from adding long-term hormone therapy to salvage radiation therapy if their PSA levels are low; instead, they might be at higher risk of dying from causes other than cancer, like cardiac or neurological problems, a…
